Pulmatrix

About:

Pulmatrix develops inhaled therapies for the treatment, prevention and transmission of infectious and progressive respiratory diseases.

Website: http://www.pulmatrix.com

Twitter/X: pulmatrix_inc

Top Investors: ARCH Venture Partners, Polaris Partners, Novartis Venture Fund, 5AM Ventures, National Heart, Lung and Blood Institute

Description:

Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes.